Cargando…
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
We are now in an aging population, so neurological disorders, particularly the neurodegenerative diseases, are becoming more prevalent in society. As per the epidemiological studies, Europe alone suffers 35% of the burden, indicating an alarming rate of disease progression. Further, treatment for th...
Autores principales: | Kanwar, Jagat R, Sriramoju, Bhasker, Kanwar, Rupinder K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405884/ https://www.ncbi.nlm.nih.gov/pubmed/22848160 http://dx.doi.org/10.2147/IJN.S30919 |
Ejemplares similares
-
Neurobehavioral burden of multiple sclerosis with nanotheranostics
por: Sriramoju, Bhasker, et al.
Publicado: (2015) -
Nanoformulated cell-penetrating survivin mutant and its dual actions
por: Sriramoju, Bhasker, et al.
Publicado: (2014) -
Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn
por: Roy, Kislay, et al.
Publicado: (2016) -
Chimeric aptamers in cancer cell-targeted drug delivery
por: Kanwar, Jagat R, et al.
Publicado: (2011) -
Molecular targets in arthritis and recent trends in nanotherapy
por: Roy, Kislay, et al.
Publicado: (2015)